Mbrace Therapeutics Raises $85 Million Series B Financing To Advance Oncology Pipeline Of Innovative Antibody Drug Conjugate Candidates
Amount Raised
$85 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalInvestors
Description
MBraceTM Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, announced the completion of an $85 million Series B financing, bringing the company’s total raised to $110 million. Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.
Quick answer
MBrace Therapeutics raised $85 Million in a Series B round, dated November 14, 2023. Investors: Alta Partners, Venrock, Cowen Healthcare Investments, Avidity Partners, The Rise Fund, TPG Life Sciences Innovations and Tpg. MBrace Therapeutics is based in San Diego, California, United States.
- How much did MBrace Therapeutics raise?
- MBrace Therapeutics raised $85 Million in a Series B round on November 14, 2023.
- Who invested in MBrace Therapeutics?
- Alta Partners, Venrock, Cowen Healthcare Investments, Avidity Partners, The Rise Fund, TPG Life Sciences Innovations and Tpg are named as investors in this round.
- What does MBrace Therapeutics do?
- MBrace is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer.
- Where is MBrace Therapeutics based and how big is it?
- MBrace Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at MBrace Therapeutics?
- Fundz holds 1 contact at MBrace Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as MBrace Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
- Os Therapies raised $700K on December 8, 2023.
- Ratio Therapeutics raised $51M on December 7, 2023.
- On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
- MAIA Biotechnology raised $4.9M (Seed) on November 15, 2023.
- EyeBio raised an undisclosed amount (Series A) on November 14, 2023.
Who to call at MBrace Therapeutics, and when
A new round usually means MBrace Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MBrace Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MBrace Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MBrace Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MBrace Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansMBrace Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.